Preventive healthcare, rise in chronic diseases, aging population, convenience and accessibility offered by self-testing kits are some of the key factors fueling the market growth.
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport
Commercial launch of INPEFA® continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of.